In the study of Hill et al. [30], the authors analyzed the epidemiology of infections during the first 90 days after CD19 CAR-T cell immunotherapy in 133 patients with relapsed or refractory B-cell malignancies, 47 of which with B-ALL, and identify factors that predispose them to a higher risk of infection. The gene discussed is CD19; the disease is infection.